Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants-Reference-Cited by-同舟云学术

Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants

Published:2024-08 Issue:21 Volume:42 Page:126164
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Gebretekle Gebremedhin B.,Yeung Man Wah,Ximenes Raphael,Cernat Alexandra,Simmons Alison E.,Killikelly April,Siu Winnie,Rafferty Ellen,Brousseau Nicholas,Tunis Matthew,Tuite Ashleigh R.

Funder

Natural Sciences and Engineering Research Council of Canada

Publisher

Elsevier BV

Reference53 articles.

1. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis;Li;Lancet,2022

2. Incidence of hospitalization for respiratory syncytial virus infection amongst children in Ontario, Canada: a population-based study using validated health administrative data;Pisesky;PLoS One,2016

3. Pediatric RSV-associated hospitalizations before and during the COVID-19 pandemic;Bourdeau;JAMA Netw Open,2023

4. Burden of illness in infants and young children hospitalized for respiratory syncytial virus: a rapid review;Wingert;Can Commun Dis Rep,2021

5. Summary of the National Advisory Committee on immunization (NACI) statement update on the recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants;Moore;Can Commun Dis Rep,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nirsevimab—a breakthrough in respiratory syncytial virus bronchiolitis;The Lancet Child & Adolescent Health;2024-08